IL2 and neoplasm: One of the pioneering work was published more than 20 years ago by Quintin-Colonna and collaborators, describing the efficacy of repeated local injections of human IL-2-genetically engineered xenogeneic cells at the primary tumor site after its surgical removal in association to radiotherapy [131].